Catalyst AGAMREE® Now Commercially Available in U.S. for Treatment of Duchenne

 AGAMREE^® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile

Available in the U.S. by Prescription for Patients Aged Two Years and Older

Catalyst Pathways^® Program will Support AGAMREE Patients and Available to Help Ensure DMD Patients Affordable Access and Product Education

https://www.biospace.com/article/releases/catalyst-pharmaceuticals-announces-agamree-now-commercially-available-in-the-u-s-for-the-treatment-of-duchenne-muscular-dystrophy-dmd-/